No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Dr. Konstantin Kousoulas, World’s Most Eminent Virologist Is Named VP of Scientific Affairs at Rational Vaccines

Editor: What To Know

  • His work in the field of HSV gives hopes to the millions of patients who are in desperate need of a better standard of care and to all of us who work to defeat this heinous virus,”.
  • Konstantin Kousoulas is a professor of virology and biotechnology in the Louisiana State University Department of Pathobiological Sciences and director of the Division of Biotechnology and Molecular Medicine (BioMMED).
  • He has also constructed and patented herpes simplex viruses that have been shown to be highly effective as preventative and therapeutic vaccines for herpes genital and ocular infections, as well as potent adjuvants for cancer immunotherapy, approaches in animal models.

Dr. Konstantin Kousoulas, a leading virologist will work to further Rational Vaccines core mission of eradicating the world of the herpes simplex virus.

“Dr. Kousoulas is one of the world’s most eminent virologists. His work in the field of HSV gives hopes to the millions of patients who are in desperate need of a better standard of care and to all of us who work to defeat this heinous virus,” said Rational Vaccines CEO Agustin Fernandez. “No one understands this virus better than Gus. His addition to the team brings us one step closer to our goal of eradicating the Herpes pandemic.”

Dr. Konstantin Kousoulas is a professor of virology and biotechnology in the Louisiana State University Department of Pathobiological Sciences and director of the Division of Biotechnology and Molecular Medicine (BioMMED).

Dr. Konstantin Kousoulas research focuses primarily on the molecular biology and the immunopathogenesis of human herpes viruses. He has extensively utilized herpes simplex viral vectors for vaccine development and cancer treatment. He has also constructed and patented herpes simplex viruses that have been shown to be highly effective as preventative and therapeutic vaccines for herpes genital and ocular infections, as well as potent adjuvants for cancer immunotherapy, approaches in animal models.

Kousoulas’ work has been published in a variety of scientific publications including the Journals of Veterinary Microbiology and Journal of Virology as well as featured by news outlets around the globe. He received his Master’s and doctorate degrees from Pennsylvania State University in Biophysics and Molecular Cell Biology, respectively. Kousoulas received postdoctoral training under Dr. Bernard Roizman at the University of Chicago and with Dr. Lenore Pereira at the University of California at San Francisco.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

VeraClinic: Pioneering Personal Transformation Through Hair Transplantation and Cosmetic Surgery in Turkey

As a testament to Turkey's legacy in the world of aesthetic medicine, VeraClinic invites you to discover the transformative power of our hair transplantation and cosmetic surgery services.

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy